Clinical Trial Update: A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability [Phase 2]

View source ↗

Summary

A multinational Phase 2 randomized, double-blind, placebo-controlled study assessing safety and tolerability in relapsing multiple sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Investigational drug (not disclosed)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Relapsing Multiple Sclerosis | Phase 2 | Status: WITHDRAWN